Condition category
Respiratory
Date applied
30/09/2005
Date assigned
30/09/2005
Last edited
05/04/2011
Prospective/Retrospective
Retrospectively registered
Overall trial status
Stopped
Recruitment status
Stopped

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Emma Baker

ORCID ID

Contact details

St George's Hospital
University of London
Cranmer Terrace
Tooting
London
SW17 0RE
United Kingdom
+44 (0)20 8725 5383
ebaker@sgul.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N0236143719

Study information

Scientific title

Acronym

Study hypothesis

To determine whether nasal application of phloridzin, a sodium-glucose co-transporter (SGLT-1) inhibitor, alters nasal potential difference demonstrating SGLT-1 function.

Ethics approval

Wandsworth REC (UK)

Study design

In vivo pharmacological study

Primary study design

Interventional

Secondary study design

Other

Trial setting

Not specified

Trial type

Not Specified

Patient information sheet

Condition

Respiratory: Chronic obstructive pulmonary disease (COPD)

Intervention

Nasal potential difference: between the 'sensing' electrode in contact with the nasal epithelium, and the 'reference' electrode, a butterfly needle inserted under the skin of the forearm, is measured. Phloridzin in Ringer's solution will then be additionally perfused onto the nasal epithelium and any further change in nasal PD recorded. On a second visit a repeat of the above protocol will be carried out with phloridzin followed be amiloride.

Intervention type

Drug

Phase

Not Specified

Drug names

phloridzin

Primary outcome measures

Changes in the measured nasal potential difference with phloridzin

Secondary outcome measures

No secondary outcome measures

Overall trial start date

01/10/2002

Overall trial end date

01/12/2007

Reason abandoned

Not a clinical trial

Eligibility

Participant inclusion criteria

Healthy, non-smoking volunteers with normal nasal mucosa and random plasma glucose <7mmol/l.

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

10

Participant exclusion criteria

1. Nasal disease
2. Diabetes mellitus
3. Pregnancy

Recruitment start date

01/10/2002

Recruitment end date

01/12/2007

Locations

Countries of recruitment

United Kingdom

Trial participating centre

St George's Hospital
London
SW17 0RE
United Kingdom

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Government

Funder name

St George's Healthcare NHS Trust (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

No External Funding

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

NHS R&D Support Funding

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes